News

Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

Marleen I. Meyers, MD, emphasizes prioritizing whole foods, particularly fruits and vegetables, over relying on supplements for patients with cancer.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

Bernd Kasper, MD, PhD, discusses the key efficacy results from the updated analysis of the phase 3 DeFi trial of nirogacestat in desmoid tumors.

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Shirish M. Gadgeel, MD, provides and overview of the MARIPOSA trial of lazertinib and amivantamab vs osimertinib in EGFR-mutated advanced or metastatic NSCLC.

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Nicolas Girard, MD, PhD, discusses data from the COCOON trial for patients with EGFR-mutant advanced non–small cell lung cancer.

Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory warrant further investigation.

Trisha Wise-Draper, MD, PhD, provides an overview of the advancements for the management of head and neck cancers.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive non–small cell lung cancer.

Firas Eladoumikdachi, MD, FACS, and M. Michele Blackwood, MD, FACS, assess preoperative radiation boosts in breast cancer care.

Final overall survival data from the MARIPOSA trial show that amivantamab and lazertinib improves survival vs osimertinib in EGFR-mutated NSCLC.

Early trial results show combining the oncolytic virus olvi-vec with chemotherapy led to disease control and tolerable safety in extensive-stage small cell lung cancer.

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.

Alan H. Bryce, MD, discusses ongoing research in radioligand therapies.

A phase 3 trial will evaluate IMNN-001, the first immunotherapy to show an overall survival benefit in ovarian cancer.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors.

Belzupacap sarotalocan showed rapid immune activation and a favorable safety profile as a treatment for non–muscle-invasive bladder cancer.

Marleen I. Meyers, MD, discusses how for patients with cancer, diet influences prevention, treatment outcomes, and long-term survivorship.

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ovarian cancer.

Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and overall survival.

A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian and breast cancers.